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Purpose: To evaluate progression rates with dorzolamide compared with other hypotensive 
agents in primary open-angle glaucoma.
Methods: Patients who were treated over 5 years with dorzolamide versus other hypotensive 
agents were reviewed. The groups were matched by intraocular pressure, cardiovascular his-
tory, and age.
Results: In 50 matched pairs, 2 (4%) of dorzolamide and 7 (14%) of control patients suffered 
glaucomatous progression (p = 0.09). Progressed dorzolamide patients had pressures of 13 
versus 15–20 mmHg in the control group. Control patients progressed after 26.4 months and 
dorzolamide patients after 38.9 months.
Conclusions: Although the results were not statistically signiﬁ  cant, this pilot trial demonstrated 
a trend towards less glaucomatous progression in patients treated with an assumed active blood 
ﬂ  ow product. In addition, progression was delayed and occurred at lower pressures in the 
active blood ﬂ  ow group. This pilot trial suggests that future prospective, long-term, clinical 
outcomes studies in patients treated with a medicine with a positive ocular blood ﬂ  ow effect 
may be warranted.
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Introduction
Much information now exists in the literature conﬁ  rming that the reduction of intra-
ocular pressure helps prevent, but does not absolutely preclude, progression of glau-
coma (Mao et al 1991; Stewart et al 1993, 2000; AGIS Investigators 2000; Lichter 
et al 2001; Konstas et al 2004). Because some patients still progress despite pressure 
reduction, other risk factors may exist that allow some patients to progress despite 
treatment. However, little information is available that identiﬁ  es these “other” speciﬁ  c 
risk factors that cause glaucomatous progression.
Although controversial, decreased ocular blood ﬂ  ow, as well as poor ocular perfu-
sion pressure associated with reduced systemic blood pressure, have been frequently 
discussed as potential risk factors for the progression of glaucoma (Stewart 1998; 
Hayreh et al 1999). Unfortunately, little long-term information exists indicating that 
blood ﬂ  ow is a part of the pathogenesis of glaucoma or that improving blood ﬂ  ow 
provides improved clinical outcomes more than lowering the intraocular pressure in 
isolation (Stewart 1998). Further, several problems exist in designing a trial to deter-
mine any inﬂ  uence of blood ﬂ  ow in glaucoma, which are not limited to, but include: 
ﬁ  rst, that the potential improved ocular hemodynamics from merely reducing the 
intraocular pressure is a confounding variable to an actual primary blood ﬂ  ow effect; 
and second, that the expense of such a study would be high because of the required 
long-term, double-masked, parallel, multi-center, prospective, trial design.Therapeutics and Clinical Risk Management 2007:3(5) 726
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An initial cost- and time-effective method for evaluating 
clinical outcomes from a potential increased ocular blood 
ﬂ  ow might be a retrospective review of existing patient 
records. In such a design a potential blood ﬂ  ow effect could 
be isolated, at least in part, by matching patients by intra-
ocular pressure between groups treated with medicines that 
demonstrate improved ocular hemodynamics to a control 
that does not have a blood ﬂ  ow effect.
The purpose of this pilot study was to evaluate the 
long-term progression rates of primary open-angle glau-
coma patients treated with an agent that has been shown 
to improve ocular hemodymanic characteristics clinically 
(ie, dorzolamide, active blood ﬂ  ow agent) versus medicines 
that have not shown a conclusive and consistent clinical 
ocular hemodynamic effect (control group, non-active 
blood ﬂ  ow agent). Patients were matched 1:1 by intraocular 
pressure so any differences in progression rates between 
groups might be potentially ascribed to non-pressure-re-
lated factors.
Materials and methods
Patients
Patients were included in this retrospective analysis who 
fulﬁ  lled the following conditions: 40 to 80 years of age; a 
clinical diagnosis of primary open-angle glaucoma in at least 
one eye (study eye); treated with at least 5 years follow-up 
from July 1997 by dorzolamide (Trusopt™, Merck & Co., 
Whitehouse Station, NJ, USA) (dorzolamide group: assumed 
active ocular blood ﬂ  ow agent) or ocular hypotensive agents 
(assumed to be both non-active blood ﬂ  ow agents and non-
active neuroprotective agents) (Table 1). 
Generally medicines were classiﬁ  ed as non-active neuro-
protective or blood ﬂ  ow product based on blood ﬂ  ow studies. 
We did not use animal or in vitro studies to make a clinical 
blood ﬂ  ow classiﬁ  cation because differing medicine concen-
trations and availability of the active molecule to the recep-
tors in vitro can alter results from what might be observed 
clinically. Consequently, based on clinical trials dorzolamide, 
betaxolol, and acetazolamide were classiﬁ  ed as a blood ﬂ  ow 
product (Bonte et al 1988; Turacli et al 1998; Bernd et al 
2001). Unoprostone was classiﬁ  ed as both a neuroprotective 
and blood ﬂ  ow product (Melamed 2002). Brimonidine was 
classiﬁ  ed as a neuroprotective product (Yoles et al 1999). 
Further, although latanoprost has been known to improve 
blood ﬂ  ow the results are inconsistent and are thought to be 
due to its marked reduction of intraocular pressure and not 
an independent effect on ocular vascularity.
Within the 5-year follow-up, patients must have been 
treated for 50% of the total follow-up time with the dor-
zolamide/timolol maleate ﬁ  xed (Cosopt™, Merck & Co., 
Whitehouse Station, NJ) or unﬁ  xed combination and 80% 
of the follow-up time patients must have been treated with 
dorzolamide (as a single agent or as the ﬁ  xed combination). 
However, patients may have used an assumed active blood 
flow or neuroprotective agent(s) for up to 25% of the 
follow-up period in either group (Table 1). Patients may have 
been treated with any number of medications or surgeries. 
At visit 1 patients must have had a mean intraocular pres-
sure of 21 mmHg, have been on a stable medical regimen 
for at least one visit prior to visit 1, and have had a mean 
intraocular pressure over the follow-up period of 10 to 21 
mm Hg inclusive.
Patients were excluded from the analysis who had: any 
abnormality preventing reliable applanation tonometry in 
study eye; any opacity or patient uncooperativeness that 
restricted adequate examination of the ocular fundus or 
anterior chamber in the study eye or poor follow-up (less 
than 8 visits over 5 years; or did not have baseline visual 
Table 1 Classiﬁ  cation of glaucoma agents and number of patients with each medicine
Name  Control  Dorzolamide  Class of agent  Allowed use
Dorzolamide 1  19  Blood  ﬂ  ow   Study group only
DTFC 0  44  Blood  ﬂ  ow   Study group only
Prostaglandin analogs  26  23  Non-active   Either group
Non-selective b-blockers  43  36  Non-active   Either group
Apraclonidine  1  2  Non-active   Either group
Betaxolol 1  7  Blood  ﬂ  ow   25% in either group
Unoprostone 1  2  Blood  ﬂ  ow and neuroprotective   25% in either group
Brimonidine 0  14  Neuroprotective    25% in either group
Pilocarpine  8  7  Non-active   Either group
Systemic CAI  1  0  Blood ﬂ  ow   25% in either group
Abbreviations: CAI, carbonic anhydrase inhibitors; DTFC, dorzolamide/timolol maleate ﬁ  xed combination.Therapeutics and Clinical Risk Management 2007:3(5) 727
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ﬁ  eld and optic disc exam within 12 months before or within 
6 months after visit 1. 
Procedures
A HIPPA waiver was obtained for this study. Patients who 
met the inclusion and exclusion criteria had the following 
recorded: date, age, race, gender, cardiovascular history, 
right/left eye, and glaucoma surgical and medication his-
tory. One eye was randomly chosen to be included if both 
eyes qualiﬁ  ed. The ophthalmic examinations recorded were: 
Goldmann applanation tonometry, Snellen visual acuity, and 
the most recent dilated funduscopic exam of the optic nerve 
and the visual ﬁ  eld (available at Month -12 to Month -6). 
The visual ﬁ  eld was performed using threshold techniques 
on the Humphrey Field Analyzer (Humphrey Instruments, 
San Leadro, CA). Glaucoma medicines were also recorded 
at each visit.
The matching criteria were then determined to be: 
the mean intraocular pressure at every visit over 5 years 
(± 2 mmHg), age at visit 1 (± 10 years) and the presence or 
absence of cardiac disease. A positive cardiac history includ-
ed, but was not limited to, systemic hypertension, ischemic 
heart disease, angina, myocardial infarction, coronary artery 
bypass graft, or angioplasty. The patient records for this study 
were reviewed in alphabetical order in the glaucoma practice 
of one of the authors (DGD). Data collection was performed 
by the clinical glaucoma research fellow (SD) and several 
experienced ophthalmic research coordinators. All charts 
that met the inclusion and exclusion criteria were available 
for matching and no chart was excluded from consideration. 
The ﬁ  rst appropriate match found was used for the study. The 
principal investigator (WCS), clinical investigator (DGD), 
and the lead coordinator (JAS) were masked to patient match-
ing procedures. Once matching was complete the data were 
entered and analyzed by a separate team including the lead 
investigator (WCS).
At each interim visit up to 5 years and the exit visit the 
following information was collected: date, glaucoma medi-
cations and surgeries, intraocular pressure, visual acuity, 
and any optic disc or ﬁ  eld exam results. If the patient was 
noted to progress this was noted as well and the patient was 
discontinued from the follow-up process. If progression oc-
curred, the reason for progression, if available, was noted. 
Progression was diagnosed from the clinical interpretation 
on the patient’s record as noted by the investigator (DGD). 
The clinical criteria for progression were those generally 
accepted in routine practice including progressive optic 
nerve head thinning, saucerization, or the appearance of 
a nerve ﬁ  ber layer hemorrhage at, or close to, the optic 
nerve head and/or worsening or the development of visual 
ﬁ  eld defect including nasal step or Seidel’s, arcuate, or 
pericentral scotoma.
Statistics
All data analyses were two-sided and a p value of 0.05 was 
used to declare signiﬁ  cance. The primary safety variable, 
glaucomatous progression, was analyzed by a McNemar 
test (Book 1978). Since this was a pilot trial the study was 
not powered for sample size. Age and intraocular pressure 
were analyzed by a t-test. Visual ﬁ  eld, visual acuity, and 
optic disc were all analyzed by a Wilcoxon sign rank test. 
Gender, right/left eye, presence of cardiovascular disease, 
types of pre-study glaucoma surgical procedures, car-
diovascular diagnosis, and intra-study glaucoma surgical 
procedures were analyzed by a McNemar test (Book 1978). 
Race and glaucoma medication history were evaluated by a 
chi square test.
Results
Patients
This analysis included 250 patients. From this, 50 matched 
pairs were compiled into the blood ﬂ  ow (dorzolamide, dor-
zolamide/timolol ﬁ  xed combination) and non-blood ﬂ  ow 
(control) groups. The classiﬁ  cation of medications used for 
this trial is presented in Table 1. Patient characteristics are 
shown in Table 2. There were no signiﬁ  cant differences 
between groups for any parameter except the dorzolamide 
group had marginally greater baseline visual ﬁ  eld damage 
(p = 0.05) and a greater number of laser trabeculoplasties 
prior to the study with dorzolamide (p = 0.01). All patients 
had primary open-angle glaucoma.
Glaucomatous progression
The matched patient pairs of patients in whom one pro-
gressed, including age, intraocular pressure and cardiovas-
cular history, are shown in Table 3. The mean intraocular 
pressure in the dorzolamide group was 15.8 ± 2.4 and 
15.8 ± 2.0 mmHg in the control group (p = 0.87). In the 
control group 7 patients progressed (14%) and 2 (4%) in the 
dorzolamide group during follow-up (p = 0.09). This was 
not a signiﬁ  cant difference. The mean follow-up time for the 
progressed patients in the study for the control group was 
26.4 ± 17.5 and 38.9 ± 14.9 months in the dorzolamide group 
(p = 0.43). For the stable patients the mean follow-up time for 
the progressed patients in the control group was 59.6 ± 2.2 
and 58.4 ± 7.4 months in the dorzolamide group (p = 0.22). Therapeutics and Clinical Risk Management 2007:3(5) 728
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Visual ﬁ  eld defects     
0  Peripheral constriction or none  28 (56)  22 (44)  0.05
1  Seidel’s scotoma/paracentral   11 (22)  8 (16) 
 scotoma/nasal  step
2  Arcuate scotoma – one hemiﬁ  eld  8 (16)  14 (28) 
3  Arcuate scotoma – two hemiﬁ  elds  3 (6)  5 (10) 
4  Deep diffuse depression  0 (0)  1 (2) 
Fundus examinations ﬁ  ndings     
0  Normal  2 (4)  1 (2)  0.07
1  Neural rim thinning  35 (70)  30 (30) 
2  Neural rim notching or saucerization  12 (24)  15 (30) 
3  Thin nasal rim  0 (0)  1 (2) 
4  Total glaucomatous cupping  1 (2)  3 (6) 
Pre-study enrollment
glaucoma surgeries     
  Laser trabeculoplasty  14 (28)  28 (56)  0.01
  Trabeculectomy  2 (4)  0 (0)  0.20
Intra-study enrollment 
glaucoma surgeries     
  Laser trabeculoplasty  8 (16)  12 (24)  0.47
  Trabeculectomy  0 (0)  1 (2)  0.40
  Argon laser iridotomy  0 (0)  1 (2)  0.40
Cardiovascular history      
 Yes  19  (38)  19  (38)  1.00
 No  31  (62)  31(62) 
Cardiovascular diagnosis 
(>1 incidence)     
  Hypertension  15 (30)  17 (34)  1.00
  Coronary artery disease  3 (6)  1 (2)  0.62
 Arrhythmia  1  (2)  1  (2)  0.48
Table 2 Patient characteristics
    Control (%)  Dorzolamide (%)  p value
Race    
 Caucasian  26  (52)  31  (62)  0.57
  Black  22 (44)  16 (32) 
 Asian  1  (2)  1  (2) 
 Hispanic  1  (2)  2  (4) 
Gender    
 Male  18  (36)  20  (40)  0.73
  Female  32 (64)  30 (60) 
Age    
  Mean  63.6 ± 8.6  63.8 ± 10.6  0.81
  40 0  (0)  1  (2) 
 41–50  5  (10)  7  (14) 
 51–60  12  (24)  10  (20) 
 61–70  22  (44)  17  (34) 
 71–80  11  (22)  13  (26) 
 80 0  (0)  2  (4) 
Eye    
 Right  23  (46)  25  (50)  0.84
 Left  27  (54)  25  (50) 
Visual acuity         
 20/20–20/25  29  (58)  22  (44)  0.50
 20/30–20/50  15  (30)  22  (44) 
 20/60–20/70  3  (6)  3  (6) 
 20/80–20/200  2  (4)  2  (4) 
 7/200–20/400  1  (2)  1  (2) Therapeutics and Clinical Risk Management 2007:3(5) 729
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Table 3 Matched pairs (aProgressed)
   Control   Dorzolamide
Pair #  Age (years)  Cardiac history  IOP (mmHg)  Age (years)  Cardiac history  IOP (mmHg)
1 69  Yes  16  66  Yes  17
2 58  Yes  16  64  Yes  17
3 61  No  15  62  No  16
4 46  No  16  46  No  16
5 54  No  15  60  No  16
6 59  No  16  56  No  17
7 71  No  16  61  No  18
8 69  Yes  13  68  Yes  13a
9 65  Yes  18  75  Yes  19
10 78  No  17  80  No  19
11 53  No  16  48  No  18
12 53  No  13  63  No  13
13 62  No  17  60  No  18
14 77  Yes  16*  83  Yes  14
15 54  No  17  55  No  17
16 60  No  17  60  No  16
17 49  Yes  19  46  Yes  21
18 58  No  14  49  No  16
19 60  No  17  55  No  18
20 70  No  12  71  No  11
21 59  No  13  63  No  12
22 74  No  15  71  No  15
23 69  Yes  18  76  Yes  16
24 74  No  14  76  No  16
25 50  No  16  50  No  14
26 63  No  12  64  No  12
27 73  Yes  16  75  Yes  16
28 53  No  19  49  No  19
29 76  No  14  81  No  12
30 76  No  16  70  No  17
31 63  No  16  58  No  14
32 74  Yes  13  78  Yes  14
33 69  No  17  66  No  19
34 58  No  18  53  No  16
35 67  Yes  17a  68  Yes  17
36 64  No  19a  63  No  20
37 70  Yes  15a  79  Yes  14
38 68  No  20a  76  No  18
39 65  Yes  18  72  Yes  18
40 67  Yes  15a  64  Yes  13
41 71  Yes  16  72  Yes  15
42 44  No  13  46  No  11
43 65  No  12  71  No  13*
44 61  Yes  19a  55  Yes  17
45 67  Yes  15  68  Yes  16
46 76  Yes  17  70  Yes  17
47 66  No  15  57  No  14
48 61  No  14  69  No  15
49 63  Yes  14  62  Yes  12
50 49  Yes  19  40  Yes  18
Abbreviations: IOP, intraocular pressure. Therapeutics and Clinical Risk Management 2007:3(5) 730
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These follow-up times differences were not statistically dif-
ferent for either progressed or stable patients.
The distribution of the intraocular pressure for the 
matched pairs, and whether or not they progressed, are 
shown in Figure 1. The two patients who progressed in 
the dorzolamide group had lower intraocular pressures 
(both 13 mmHg) than in the control group (range 15–20 
mmHg). 
Discussion
Dorzolamide is a topical anhydrase inhibitor that is an ac-
tive ingredient in two commercially available formulations 
(Trusopt™ and Cosopt™, Merck & Co., Whitehouse Station, 
NJ, USA). Dorzolamide is chemically related to acetazol-
amide (Diamox™, Wyeth, Madison, NJ, USA), a systemic 
carbonic anhydrase inhibitor. However, acetazolamide also 
has a systemic effect on the central nervous system vasodila-
tion (Bonte et al 1988). The molecular basis for this action 
is not yet understood. Dorzolamide has also been shown to 
have a vascular effect in the eye. Consistent with this ﬁ  nd-
ing, Harris and associates have shown in several studies 
using color doppler imaging that dorzolamide as well as the 
dorzolamide/timolol ﬁ  xed combination in normals, primary 
open-angle, and low tension glaucoma patients may increase 
red blood cell velocity in retinal vessels (Harris et al 2000, 
2001, 2003a). 
Theoretically this positive ocular blood ﬂ  ow effect could 
help limit progression to glaucoma (Bernd et al 2001). Poor 
blood ﬂ  ow has been associated with the progression of 
glaucoma by several lines of evidence (Ciofﬁ   2001). First, 
epidemiologic factors: a clinical history of generally systemic 
atherosclerotic or vasospastic disease has been linked to a 
greater incidence of elevated intraocular pressure and pri-
mary open-angle glaucoma (Stewart 1990). Speciﬁ  c related 
symptoms and signs have been: elevated blood pressure, 
cardiovascular disease, peripheral vasospasm, migraines, 
diabetes, decreased diastolic ocular perfusion pressure, and 
night-time blood pressure dips, as well as symptoms of cold 
hands and feet (Shields 1982; Gasser et al 1990; Stewart 
1990; Akarsu and Bilgili 2004; Fraser and Wormald 2004; 
Zimmerman et al 2004). Second, clinical ocular hemody-
namics in glaucoma and ocular hypotensive patients have 
Figure 1 The ﬁ  gure shows the distribution and linear regression of the intraocular pressure for the matched pairs and whether they progressed for each matched pair on 
dorzolamide (square), control patients (triangle), and matched pairs that did not progress (diamond).
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shown worsened ocular blood ﬂ  ow measures, compared with 
normals, including: peak blood ﬂ  ow (probably choroidal), 
retinal blood ﬂ  ow, resistivity index and red blood cell velocity 
(Stewart 1998; Akarsu and Bilgili 2004; Galassi et al 2003). 
In addition, several other studies have speciﬁ  cally noted that 
progressed glaucoma patients demonstrate worse blood ﬂ  ow 
indices compared to non-progressed patients (Galassi et al 
2003; Satilmis et al 2003; Flammer et al 2002; Gherghei 
et al 2000). Third, systemic vascular disease relationships: 
Stroman and co-workers have shown that patients with low 
tension glaucoma have increased white matter lesions in the 
brain indicative of central nervous system vascular disease 
(Gherghei et al 2000). In addition, Harris and associates 
noted blood ﬂ  ow abnormalities in the central carotid artery 
in patients with glaucoma indicating a potential association 
to atherosclerotic disease in the central nervous system vas-
culature (Harris et al 2003b).
The above studies are limited by several factors: ﬁ  rst, 
the epidemiologic association of cardiovascular history to 
glaucoma is not completely consistent; second, epidemio-
logic, as well as clinical systemic blood ﬂ  ow, relationships to 
glaucoma have not been shown to be causal, but may be only 
a casual association; and third, it remains unclear whether 
reduced clinical blood ﬂ  ow measurements in glaucoma are a 
primary (pathogenic) or a secondary effect (due to a reduced 
blood ﬂ  ow requirement from glaucomatous optic nerve tissue 
loss). Unfortunately, studies have not yet evaluated baseline 
blood ﬂ  ow parameters to long-term clinical outcomes or 
shown that improving these blood ﬂ  ow parameters prevents 
progression.
The purpose of this pilot study was to evaluate the 
long-term progression rates of primary open-angle glau-
coma patients treated with an assumed blood ﬂ  ow active 
ocular hypotensive agent (ie, dorzolamide group) versus a 
non-blood ﬂ  ow active agent (control group). Patients were 
matched 1:1 by intraocular pressure so any differences in 
progression rates between groups might be related to non-
pressure related factors.
This study showed over 5 years that patients in the dorzol-
amide group progressed in 4% of cases compared with 14% 
in the control group. In addition, progression was delayed 
in the dorzolamide-treated patients (39 months) compared 
with the control group patients (26 months). Since patients 
were matched for intraocular pressure, any divergence in 
progression rates between treatment groups should not 
have resulted from differences in the ocular hypotensive 
treatment effect. The differences found between the groups 
in the study, however, were not statistically signiﬁ  cant and 
represent only a trend towards an improvement in progres-
sion in the dorzolamide group. Although progression rates 
were difﬁ  cult to compare between studies, in our study the 
percentage of patients who worsened were comparable to 
CIGTS and less than the EMGT (Lichter et al 2001; Heijl 
et al 2002). However, progression rates could have varied 
with a larger patient sample in our study.
Few differences existed between groups besides slightly 
greater visual ﬁ  eld damage and a greater number of laser 
trabeculoplasties prior to the study with dorzolamide. Some 
authors have speculated that patients with greater visual 
ﬁ  eld damage are more likely to progress at lower pressures, 
which could have led towards greater progression for the 
dorzolamide group (Stewart et al 1993). However, a greater 
number of trabeculoplasties should not have inﬂ  uenced the 
results because the pressures were matched between treat-
ment groups.
An additional ﬁ  nding was that the progressed patients 
in the dorzolamide group had lower mean pressures (both 
13 mmHg) over the follow-up period compared with the 
control group (range 15–20 mmHg). The reason for this was 
not apparent. It may suggest that patients who progressed in 
the dorzolamide group potentially had particularly diseased 
eyes, or poor perfusion pressure, and progressed despite 
the low pressure and any potential blood ﬂ  ow effect from 
dorzolamide. Previous studies have noted that progression of 
glaucoma happens at a very low rate at pressures of 12–13 
mmHg (Mao et al 1991; Stewart et al 1993; AGIS Investiga-
tors 2000; Stewart et al 2000).
Although this study raises the question of whether a 
potential ocular blood ﬂ  ow effect might inﬂ  uence long-term 
clinical outcomes in glaucoma, the results are based on sev-
eral unproven assumptions: ﬁ  rst, the observed clinical trend 
of reduced progression in the dorzolamide group was real 
and was not a result of mere chance; second, dorzolamide 
had an actual positive clinical blood ﬂ  ow effect; third, the 
medicines in the control group had no positive clinical blood 
ﬂ  ow or neuroprotective effect; and last, the matching criteria 
were adequate to eliminate other clinical factors that could 
have accounted for the difference in the progression rate 
between treatment groups.
Although the results were not statistically signiﬁ  cant, this 
pilot trial demonstrated a trend towards less glaucomatous 
progression in patients treated with an assumed active blood 
ﬂ  ow product. In addition, progression was delayed and 
occurred at lower pressures in the active blood ﬂ  ow group. 
Consequently, the clinical relevance of this pilot trial is to 
suggest that future prospective, long-term, clinical outcome Therapeutics and Clinical Risk Management 2007:3(5) 732
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studies in patients treated with a medicine with a positive 
ocular blood ﬂ  ow effect may be warranted.
This study did not evaluate dorzolamide or other active 
blood ﬂ  ow agents in a prospective, controlled, masked fash-
ion. Although this study had matching criteria of intraocular 
pressure, cardiac history, and age, other potentially important 
criteria such as stage of the disease were not matched. In 
addition, medicines with a neuroprotective or blood ﬂ  ow 
effect were allowed in the control group and in the active 
treatment group apart from dorzolamide in order to gain 
qualiﬁ  ed patients, even though these medicines could have 
potentially affected progression rates in both groups. In 
addition, investigators were not masked to treatments when 
collecting data for this study. Long-term studies are needed 
to conﬁ  rm any pathogenesis of reduced blood ﬂ  ow related 
to glaucoma and the beneﬁ  t of treatment. 
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